Prevalence of human papillomavirus (HPV) uterine cervix infection in White and Guarani indian populations inhabiting Misiones, Argentina;Prevalencia de la infección cervical por virus papiloma humano (HPV) en población caucásica y guaraní, residente en la provincia de Misiones, Argentina

Revista Argentina de Microbiologia

Volumn 35, Issue 4, 2003, Pages 205-213

  Tonon, S A ^a   Picconi, M A ^b   Zinovich, J B ^a   Nardari, W ^a   Mampaey, M ^a   Galuppo, J A ^a   Bos, P D ^a   Badano, I ^a   Di Lello, F ^a   Basiletti, J ^b   Gonzalez J V ^b   Alonio, L V ^b   Teyssie A R ^b  

^a UNIVERSIDAD NACIONAL DE MISIONES   (Argentina)

^b Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

Author keywords

Cervical cancer; Cervical infection; Guaranies; Human papillomavirus; Prevalence; Urban women

Indexed keywords

VACCINE;

ADULT; AGED; ARGENTINA; ARTICLE; CANCER RISK; COLPOSCOPY; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ETHNOLOGY; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; PREVALENCE; RAIN FOREST; SEROPREVALENCE; SEXUAL BEHAVIOR; SMOKING HABIT; URBAN POPULATION; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VIROLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGED; ARGENTINA; CHILD; DNA PROBES, HPV; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INDIANS, SOUTH AMERICAN; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; REPRODUCTIVE HISTORY; RISK FACTORS; RURAL POPULATION; SEXUAL BEHAVIOR; SMOKING; SOCIOECONOMIC FACTORS; TUMOR VIRUS INFECTIONS; URBAN POPULATION; UTERINE CERVICITIS;

EID: 9144262589     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. American College of Obstetricians and Gynecologists (1993) ACOG Committee Opinion: Committee on Gynecologic Practice. Washington, DC, Estados Unidos.
2. Amestoy G, Matos E, Loria D, Prince M, Moreno J, Krunfli C, et al (2000) Prevalencia de la infección por Papiloma Virus Humano del cuello uterino en la poblaciȯn del departamento de Concordia, Entre Rios. Colposcopia 11: 73-79.
3. Beaglehole R, Bonita T, Kjellström T (1994) Epidemiología básica. Publicación científica N° 551. Organización Panamericana de la Salud. Washington, DC, Estados Unidos.
4. Bernard H, Chan S, Manos M, Ong C, Villa L, Delius H, et al (1994) Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J. Infect. Dis. 170: 1077-1085.
5. Bosch F, Manos M, Muñoz N, Sherman M, Jansen A, Peto J, et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87: 796-802.
6. Bosch F, Lorincz A, Muñoz N, Meijer M, Shah K (2002) The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55: 244-265.
7. Breitburd F, Coursaget P (1999) Human papillomavirus vaccines. Cancer Biol. 9: 431-445.
8. Ferrara A, Valema J, Figeroa M, Bulnes R, Toro L, Claros J, et al (1999) Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case control study. Int. J. Cancer 82: 799-803.
9. Franco E, Villa L, Sobrinho J, Prado J, Rousseau M, Desey M, Rohan T (1999) Epidemiology of acquisition and clearence of cervical human papillomavirus infection in women froma a high-risk area for cervical cancer. J. Investig. Dermatol. 180: 1415-1423.
10. Franco E, Villa L, Richardson H, Rohan T, Ferenczy A (1997) Epidemiology of cervical human papillomavirus infection. En: Franco E (Ed), New developments in cervical cancer screening and prevention. WHO/EUROGIN monograph, Blackwell Science Ltd, Boston, p.14-22.
11. Giuliano A, Papenfuss R, Scheneider A, Nour M, Hatch K (1999) Risk factors for high risk type human papillomavirus infection among Mexican American women. Cancer Epidemiol. Biomark. Prev. 8: 615-620.
12. Harro C, Pang Y, Roden R, Hildesheim A, Wang Z, Reynolds M, et al (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. (Bethesda) 93: 284-292.
13. Ho G, Bierman R, Beardsley L, Chang C, Burk R (1998) Natural history of cervicoginal papillomavirus infection in young women. N. Engl. J. Med. 338: 423-428.
14. IARC Working group on the evaluation of carcinogenic risks to humans (1995) IARC monographs on the evaluation of the carcinogenic risks to humans, Vol. 64, Human papillomaviruses. OMS, Lyon, Francia.
15. th International Papillomavirus Conference, Resumen 0-086, Paris, Francia.
16. Koplan JP (1999) The National Breast and Cervical Cancer Early Detection Program: At-a-Glance 1999. Centers for Disease Control and Prevention, Atlanta, Estados Unidos.
17. Koutsky L, Ault K, Wheeler C, Brown D, Barr E, Alvarez F, et al (2002) A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347: 1645-1651.
18. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah K, Alonso P, et al (2001) Epidemiology of HPV infection among mexican women with normal cervical cytology. Int. J. Cancer 91: 412-420.
19. Liaw K, Glass A, Manos M., Greer C, Scott D., Sherman M., et al (1999) Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J. Natl. Cancer Inst. 91: 954-960.
20. Lin C, Lee J, Tsao Y, Shen C, Lai H, Chen S (2002) Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int. J. Cancer 102: 629-637.
21. Mandelblatt J, Lawrence W, Womack S, Jacobson D, Yi B, Hwang Y (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287: 2372-2381.
22. Muñoz N, Bosch X, de Sanjosé S, Herrero R, Castellsagué X, Shah K, et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl. J. Med. 348: 518-527.
23. Myers G, Baker C, Munger K, Sverdrup F, McBride A, Bernard H (1997) Human Papillomaviruses 1997. A compilation and analysis of nucleic acids and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N. Mex., Estados Unidos.
24. Parkin D, Pisani P, Ferlay J (1999) Estimates of the world wide incidence of 25 major cancers in 1990. Int. J. Cancer 80: 827-841.
25. Picconi M, Gronda J, Alonio L, Villa L, Sichero L, Miranda S, et al (2002) Human papillomavirus (HPV) in Quechua women from Jujuy, with high frequency of cancer of the cervix: viral types and HPV-16 variants. Medicina (Buenos Aires) 62: 209-220.
26. Rolón P, Smith J, Muñoz N, Klug S, Herrero R, Bosch X, et al (2000) Human papillomavirus infection and invasive cervical cancer in Paraguay. Int. J. Cancer 85: 486-491.
27. Schiller J, Lowy D (2001) Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin. Biol. Ther. 1: 571-580.
28. Solomon D, Schiffman M, Tarone R (2001) Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. (Bethesda) 93: 293-299.
29. Tonon S, Picconi A, Zinovich J, Liotta D, Bos P, Galuppo J, et al (1999) Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma. Infect. Dis. Obstet. Gynec. 7: 237-243.
30. Torroella M, Morsberger S, Castillo A, Mohar A, Meneses A, Ibarra M, et al (1998) HPV prevalence among Mexican women with neoplastic and normal cervixes. Gynecol. Oncol. 70: 115-120.
31. Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K, et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189: 12-19.
32. World Health Organization (1999) The current status of development of prophylactic vaccines against human papillomavirus infection. Reporte de la tercer reunión técnica, Ginebra, Suiza.
33. Zur Hausen H (1996) Papillomavirus infections, a major cause of human cancers. Biochem. Biophys. Acta 1288: 55-78.